Rigel prelim Q4 2023 total revenue ~$35.7M; TAVALISSE record $25.7M; MD Anderson deal $15M

RIGEL PHARMACEUTICALS INC

Prelim Q4 total revenue ~$35.7M: TAVALISSE net sales $25.7M (record), REZLIDHIA $3.9M.
Full-year 2023 net product sales $104.3M (+36% YoY); cash & investments $56.9M at year-end.
Strategic collaboration with MD Anderson to advance REZLIDHIA in AML and other cancers; $15M in milestones over 5 years.
Collaboration with CONNECT for Phase 2 trial of REZLIDHIA in IDH1-mutant glioma; Rigel funding up to $3M.
Phase 1b trial of R289 (IRAK1/4 inhibitor) in lower-risk MDS currently enrolling third cohort.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RIGEL PHARMACEUTICALS INC reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $35.7 million.

Period: fourth quarter and fiscal year ended December 31, 2023
Revenue: $35.7 million
Result: preliminary results

Exact text from the filing

--- EX-99.1 2 tm242328d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update · Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million · Strategic alliance with MD Anderson to advance

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-002085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.